Beta Lactam Antibiotics

PreclinicalSmall molecule

Beta Lactam Antibiotics is one of 9 small molecule programs targeting Ventilator-Associated Pneumonia. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Ventilator-Associated PneumoniaActive, not recruiting

Ventilator-Associated PneumoniaPreclinical

Active, not recruiting

Competition

Competitive Landscape

14 competitors in Ventilator-Associated Pneumonia

#DrugCompanyPhaseTrials

Doribax

Shionogi

Approved

3 2

Merrem

BB. Braun Medical Inc.

Approved

2 3

Amikin

IInsmed Incorporated

Approved

1 4

Vancocin

HHikma Pharmaceuticals LLC

Approved

1 5

Bactrim

UUniversity of California, San Francisco

Phase 3

1 6

Peridex

DDexcel Pharma Technologies Ltd.

Preclinical

1 7

Antibiotic

Pfizer

Preclinical

1 8

Bacteriophage

AAdaptive Phage Therapeutics, Inc.

Preclinical

1 9

Beta Lactam Antibiotics

OOregon Health and Science University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

Phase 2Not yet recruiting

Escherichia Coli Infections

NCT07318584

Clinical

Trials by Indication[1]

Ventilator-Associated Pneumonia1 trial

Efficacy and Safety of Prophylactic Antibiotics in Preventing Ventilator-associated Pneumonia: A Randomized, Double Blind, Placebo-controlled Trial

Enrolling by invitation·EEsraa Salah Mohamed Abdallah Eladl·N/A·NCT07203638·100 enrolled

Escherichia coli Infections1 trial

Cefotetan Therapy for Escherichia Coli Infections

Not yet recruiting·OOregon Health and Science University·Phase 2·NCT07318584·84 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Beta Lactam Antibiotics. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Beta Lactam Antibiotics compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Beta Lactam Antibiotics. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Oregon Health and Science University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: OOregon Health and Science University

Beta Lactam Antibiotics

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2028

Trials by Indication[1]

Ventilator-Associated Pneumonia1 trial

Escherichia coli Infections1 trial

References

Drug Info

Quick Facts

Related News